Valerio Therapeutics Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial

The first dose level, evaluating 3 patients of the VIO-01-101 trial has been cleared as per the recommendations of the Clinical Review Committee.



No clinically significant adverse events or...

Related Keywords

Shefali Agarwal ,Company Group ,Clinical Review Committee ,Regulatory News ,Euronext Growth Paris ,Valerio Therapeutic ,Valerio Therapeutics Medical ,Principal Investigators ,Breast Cancer ,Valerio Therapeutics ,